Image: Second state state         Europäisches Patentamt           European Patent Office         Office européen des brevets	<ul> <li>Publication number: 0 427 680 A1</li> </ul>
<b>EUROPEAN PATENT APPLICATION</b>	
<ul> <li>Application number: 90810854.1</li> <li>Date of filing: 07.11.90</li> </ul>	<ul> <li>Int. Cl.<sup>5</sup>: C07D 498/18, A61K 31/33, //(C07D498/18,311:00,273:00, 221:00)</li> </ul>
<ul> <li>Priority: 09.11.89 DE 3937336         <ul> <li>16.11.89 DE 3938132</li> <li>23.12.89 DE 3942831</li> <li>23.12.89 DE 3942833</li> <li>05.03.90 DE 4006819</li> </ul> </li> <li>Date of publication of application:         <ul> <li>15.05.91 Bulletin 91/20</li> </ul> </li> <li>Designated Contracting States:         <ul> <li>AT BE CH DE DK ES FR GB GR IT LI LU NL SE</li> <li>Applicant: SANDOZ LTD.             <ul> <li>Lichtstrasse 35</li> <li>CH-4002 Basel(CH)</li> <li>BE CH DK ES FR GB GR IT LI LU NL SE</li> </ul> </li> </ul></li></ul>	Humboldtstrasse 3 W-7850 Lörrach(DE) <b>DE</b> Applicant: SANDOZ-ERFINDUNGEN Verwaltungsgesellschaft m.b.H. Brunner Strasse 59 A-1235 Wien(AT) A-1235 Wien(AT) AT 2 Inventor: Baumann, Karl Simmeringer Hauptstrasse 36/2/29 A-1110 Vienna(AT) Inventor: Emmer, Gerhard Theresiengasse 25 A-1180 Vienna(AT)

Heteroatoms-containing tricyclic compounds.

(b) The invention concerns the compounds of formula I

EP 0 427 680 A1

Α



wherein the substituents have various significances.

DOCKE

Δ

They are prepared by several processes including epimerizing replacement, treatment with cyanogen bromide or thiophosgene, treatment with an acid having a non-nucleophilic anion, treatment with dimethylsulfoxide and acetic anhydride, acylation, treatment with an oxalyl derivative and ammonia, methylation, oxidation, deprotection and protection.

They possess interesting pharmacological activity as antiinflammatory, immunosuppressant, antiproliferative and chemotherapeutic drug resistance reversing agents.

#### EP 0 427 680 A1

#### HETEROATOMS-CONTAINING TRICYCLIC COMPOUNDS

Ι



The invention relates to the field of macrolides. It concerns the compounds of formula I

45

R

М

 $\bigcirc$ 

Δ

wherein  $R_{\rm 5}$  is chloro, bromo, iodo or azido and

R<sub>6</sub> is hydroxy or methoxy;

 $R_2$  is oxo and there is a single bond in 23,24 position; optionally protected hydrory and there is a single or a double bond in 23,24 position; or absent and there is a double bond in 23,24 position; and

50 R<sub>4</sub> is hydroxy and there is a single bond in 10,11 position; or absent and there is a double bond in 10,11 position;

or R1 is a group (b) or (d) of formula



10

5

wherein R<sub>6</sub> is as defined above;

R<sub>2</sub> is as defined above; and

R<sub>4</sub> is hydroxy and there is a single bond in 10,11 position;

or R<sub>1</sub> is a group (c) of formula

15

20

R7 H Ħ

(c)

25

30

50

wherein R6 is as defined above and

 $R_7$  is oxo; optionally protected hydroxy; methoxy; methylthiomethoxy; isobutanoyloxy; aminooxalyloxy;  $R_8R_9$ CHCOO- wherein  $R_8$  is optionally protected hydroxy or optionally protected amino and  $R_9$  is hydrogen or methyl; or p-tolyloxythiocarbonyloxy;

 $R_2$  is oxo and there is a single bond in 23,24 position; absent and there is a double bond in 23,24 position; or is optionally protected hydroxy, methoxy, methylthiomethoxy, isobutanoyloxy, aminooxalyloxy or  $R_8 R_9 CH$  COO- wherein  $R_8$  and  $R_9$  are as defined above, and there is a single or a double bond in 23,24 position; whereby for group (c)

- 1) when R<sub>7</sub> is oxo, unprotected hydroxy or methoxy then R<sub>2</sub> is other than absent and other than unprotected hydroxy or methoxy, and there is a single bond in 23,24 position;
  2) when R<sub>6</sub> is methoxy and R<sub>7</sub> is methylthiomethoxy then R<sub>2</sub> is other than absent and other than unprotected hydroxy;
  3) when R<sub>6</sub> is methoxy and R<sub>7</sub> is protected hydroxy then R<sub>2</sub> is other than optionally protected hydroxy; and
  4) when R<sub>6</sub> is hydroxy then R<sub>7</sub> is other than optionally protected hydroxy; and
  4) when R<sub>6</sub> is hydroxy then R<sub>7</sub> is other than optionally protected hydroxy; and
  6) when R<sub>6</sub> is hydroxy then R<sub>7</sub> is other than optionally protected hydroxy; and
- 45 R<sub>3</sub> is methyl, ethyl, n-propyl or allyl;

in free form and, where such forms exist, in salt form,

hereinafter referred to as "the compounds of the invention".

As is evident from formula I and the definition of the substituents when there is a single bond in 10,11 position the carbon atom to which the methyl group in 11 position is attached has the  $\beta$ -configuration and there is a hydrogen atom with the  $\alpha$ -configuration attached to the carbon atom in 11 position; when there is a double bond in 10,11 position this methyl group lies in the plane of the paper and there is no hydrogen

- atom in 11 position. When  $R_2$  is oxo no hydrogen atom is attached to the carbon atom in 24 position. When  $R_7$  is oxo the hydrogen atom shown in group (c) attached to the same carbon atom as  $R_7$  is absent.
- R<sub>1</sub> preferably is a group (c) or (d). R<sub>2</sub> preferably is unprotected hydroxy and there is a single bond in 23,24 position. R<sub>3</sub> preferably is ethyl or allyl. R<sub>4</sub> preferably is hydroxy. R<sub>5</sub> preferably is chloro. R<sub>6</sub> preferably is methoxy. R<sub>7</sub> preferably is isobutanoyloxy, aminooxalyloxy or R<sub>8</sub>R<sub>9</sub>CHCOO-. R<sub>8</sub> preferably is unprotected hydroxy or unprotected amino, especially unprotected hydroxy. R<sub>9</sub> preferably is hydrogen. When R<sub>9</sub> is other than hydrogen the carbon atom to which it is attached preferably has the (S)

Find authenticated court documents without watermarks at docketalarm.com.

#### EP 0 427 680 A1

configuration.

- Protected hydroxy preferably is hydroxy protected by a conventional hydroxy-protecting group such as formyl, tert-butoxycarbonyl, or trialkylsilyl; it especially is tert-butyldimethylsilyloxy.
- Optionally protected hydroxy as defined above under formula I for R<sub>2</sub> and R<sub>7</sub> should not be understood as including a group R<sub>2</sub> or R<sub>7</sub> which is otherwise specified, such as e.g. aminooxalyloxy or R<sub>8</sub>R<sub>9</sub>CHCOO-.
- Protected amino preferably is amino protected by a conventional amino-protecting group such as benzyloxycarbonyl or trialkylsilyl; it especially is tert-butoxycarbonyl.
  - A compound of the invention preferably is in free form. It preferably is in unprotected form.
  - A subgroup of compounds of the invention is the **compounds** Ip<sub>1</sub>, i.e. the compounds of formula I wherein
- 10 wherein

5

- $R_1$  is a group (a) wherein  $R_6$  is methoxy and
- either R5 is chloro or bromo and
- $R_4$  is hydroxy and there is a single bond in 10,11 position
- or R<sub>5</sub> is azido and
- <sup>15</sup> R<sub>4</sub> is hydroxy and there is a single bond in 10,11 position or absent and there is a double bond in 10,11 position;
  - R<sub>2</sub> is optionally protected hydroxy and there is a single or a double bond in 23,24 position; and
  - $R_3$  is as defined above under formula I;
  - in free form and, where such forms exist, in salt form.
- A further subgroup of compounds of the invention is the **compounds lp**<sub>2</sub>, i.e. the compounds of formula I wherein
  - $R_1$  is a group (c) wherein  $R_6$  is methoxy and  $R_7$  is oxo; optionally protected hydroxy; methoxy; methylthiomethoxy; aminooxalyloxy;  $R_8CH_2COO$  wherein  $R_8$  is optionally protected amino; or p-tolylox-ythiocarbonyloxy;
- PR2 is absent and there is a double bond in 23,24 position; or optionally protected hydroxy, methoxy, methylthiomethoxy or aminooxalyloxy and there is a single or double bond in 23,24 position;
  - whereby

35

55

DOCKE

- 1) when R<sub>7</sub> is oxo, unprotected hydroxy or methoxy
- then R<sub>2</sub> is other than absent and other than unprotected hydroxy or methoxy, and
- *so* there is a single bond in 23,24 position;
  - 2) when R7 is methylthiomethoxy
    - then R<sub>2</sub> is other than absent and other than unprotected hydroxy; and
    - 3) when R<sub>7</sub> is protected hydroxy
    - then R<sub>2</sub> is other than optionally protected hydroxy; and
  - R<sub>4</sub> is hydroxy and there is a single bond in 10,11 position; and
  - R<sub>3</sub> is as defined above under formula I;
    - in free form and, where such forms exist, in salt form.
    - A further subgroup of compounds of the invention is the **compounds**  $Ip_3$ , i.e. the compounds of formula I wherein
- 40  $R_1$  is a group (b) wherein  $R_5$  is methoxy,
  - $R_2$  is optionally protected hydroxy and there is a single bond in 23,24 position; or absent and there is a double bond in 23,24 position;
  - $\mathsf{R}_4$  is hydroxy and there is a single bond in 10,11 position; and
  - $\mathsf{R}_3$  is as defined above under formula I;
- 45 in free form and, where such forms exist, in salt form.
  - A further subgroup of compounds of the invention is the **compounds**  $Ip_4$ , i.e. the compounds of formula I wherein
  - R1 is a group (d),
- $R_2$  is optionally protected hydroxy and there is a single bond in 23,24 position; or absent and there is a double bond in 23,24 position;
  - R4 is hydroxy and there is a single bond in 10,11 position; and
  - $\mathsf{R}_3$  is as defined above under formula I;
  - in free form and, where such forms exist, in salt form.
    - A preferred subgroup of compounds of the invention is the compounds of formula I wherein
  - $R_1$  is a group (a) wherein  $R_5$  is as defined above under formula I and  $R_6$  is methoxy;
  - $R_2$  is optionally protected hydroxy and there is a single bond in 23,24 position;
  - $R_4$  is hydroxy and there is a single bond in 23,24 position; or absent and there is a double bond in 10,11 position; and

# DOCKET



## Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

## **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

